EUVIMEDEUVIMED entdecken
Kommentar

Clinical Outcomes After Personalized Dosimetry for 90 Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape

Michael C Soulen, William S Rilling

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.123.267035 ↗

Kurz gefasst

Kommentar in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Michael C Soulen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; and michael.soulen@pennmedicine.upenn.edu. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Embolization, Therapeutic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the United States, 90Y microspheres have been approved for more than 20 y for treatment of hepatic malignancies. Glass microspheres (TheraSphere; Boston Scientific) received a humanitarian device exemption for treatment of hepatocellular carcinoma (HCC) from the Food and Drug Administration (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsEmbolization, TherapeuticHumansPositron Emission Tomography Computed TomographyRadiometryYttrium RadioisotopesMicrospheres

Substanzen

Yttrium Radioisotopes

Autor:innen und Institutionen

  • Interventional Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; and michael.soulen@pennmedicine.upenn.edu.
  • Interventional Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin.

Zitieren

APA

Soulen, M. C., & Rilling, W. S. (2024). Clinical Outcomes After Personalized Dosimetry for 90 Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.267035

Vancouver

Soulen MC, Rilling WS. Clinical Outcomes After Personalized Dosimetry for 90 Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.267035

BibTeX
@article{Soulen2024,
  author = {Soulen, Michael C and Rilling, William S},
  title = {Clinical Outcomes After Personalized Dosimetry for 90 Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.123.267035}
}
Kostenlos starten →